Core Viewpoint - A securities class action lawsuit has been filed against F5, Inc. for alleged violations of the Securities Exchange Act of 1934 during the Class Period from October 28, 2024, to October 27, 2025, with a lead plaintiff deadline set for February 17, 2026 [1] Group 1: Lawsuit Details - The lawsuit, titled Smith v. F5, Inc., claims that F5 and its executives misrepresented the company's revenue outlook and growth potential while downplaying risks associated with seasonality and macroeconomic factors [1] - Allegations include that F5 was experiencing a significant security incident that jeopardized client security and the company's future prospects [1] - On October 15, 2025, F5 disclosed a security breach involving a nation-state threat actor, leading to a nearly 14% drop in stock price over two trading days [1] Group 2: Financial Impact - Following the security breach, F5 reported fourth quarter fiscal year 2025 results that fell significantly below market growth expectations for fiscal 2026, attributing this to the breach and announcing expected reductions in sales and renewals [1] - The stock price fell nearly 11% over two trading days after the announcement of the disappointing fiscal results [1] Group 3: Legal Process - Investors who purchased F5 securities during the Class Period can seek appointment as lead plaintiff, with the lead plaintiff representing the interests of all class members [1] - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [1] Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [1] - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [1]

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Picard Medical, Inc. of Class Action Lawsuit and Upcoming Deadlines - PMI [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Picard Medical, Inc. ("Picard" or the "Company") (NYSE: PMI). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 798 ...

Core Viewpoint - A class action lawsuit has been filed against Richtech Robotics Inc. for alleged securities fraud and unlawful business practices, following a report that questioned the company's claims about its partnership with Microsoft [1]. Group 1: Lawsuit Details - The class action lawsuit is focused on whether Richtech and its officers engaged in securities fraud or other unlawful business practices [1]. - Investors who purchased Richtech securities during the Class Period have until April 3, 2026, to apply to be appointed as Lead Plaintiff [1]. Group 2: Allegations and Impact - A report by Hunterbrook Media alleged that Richtech mischaracterized its relationship with Microsoft, claiming a "close collaboration" when it was merely a standard customer program without commercial elements [1]. - Following the report, Richtech's stock price dropped by $1.06 per share, or 20.87%, closing at $4.02 per share on January 29, 2026 [1]. Group 3: Company Background - Pomerantz LLP, the law firm handling the case, is recognized for its expertise in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for class members [1].

Core Viewpoint - A class action lawsuit has been filed against Oracle Corporation, alleging securities fraud and unlawful business practices related to its AI infrastructure strategy and financial disclosures [1]. Summary by Relevant Sections Class Action Details - Investors who suffered losses in Oracle securities are encouraged to contact Pomerantz LLP to join the class action, with a deadline to apply as Lead Plaintiff by April 6, 2026 [1]. - The lawsuit claims that Oracle and its executives made misleading statements regarding the company's capital expenditures and revenue growth expectations [1]. Allegations of Misleading Statements - The complaint alleges that Oracle's AI infrastructure strategy would lead to significant increases in capital expenditures without corresponding near-term revenue growth [1]. - It is claimed that Oracle's increased spending poses risks to its debt, credit rating, free cash flow, and project funding capabilities [1]. Impact of Analyst Reports - On September 24, 2025, S&P Global Ratings indicated that OpenAI could account for over one-third of Oracle's total revenues by fiscal 2028, raising concerns about OpenAI's ability to meet contractual obligations [1]. - Following a "Sell" rating from Rothschild & Co. Redburn on September 25, 2025, Oracle's stock price fell over 5%, with a price target set at $175, indicating a potential 40% decline [1]. Financial Performance and Stock Reactions - Oracle's Q2 fiscal year 2026 results showed revenue growth below analyst expectations, with capital expenditures exceeding estimates and negative free cash flow exceeding $10 billion, leading to an 11% drop in stock price [1]. - Reports on December 12, 2025, indicated delays in data center completion for OpenAI, further suggesting potential revenue growth delays, which contributed to additional stock price declines [1]. - On December 17, 2025, it was reported that Blue Owl Capital withdrew funding for a $10 billion data center project due to concerns over Oracle's spending and rising debt, resulting in a further 5% drop in stock price [1].

Core Viewpoint - A class action lawsuit has been filed against Masonite International Corporation, alleging securities fraud and unlawful business practices related to the company's stock repurchase activities during a specific period [1]. Group 1: Lawsuit Details - The lawsuit claims that Masonite and its officers/directors failed to disclose multiple formal acquisition offers from Owens Corning to purchase all outstanding shares of Masonite at prices significantly above the market prices during the stock repurchase period [1]. - Investors who sold Masonite common stock during the Class Period have until April 7, 2026, to request to be appointed as Lead Plaintiff in the class action [1]. Group 2: Company Background - Pomerantz LLP, the law firm handling the case, is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [1].

Core Viewpoint - A class action lawsuit has been filed against Paysafe Limited due to allegations of securities fraud and unlawful business practices, following disappointing financial results and a significant stock price drop [1]. Financial Performance - Paysafe reported third-quarter 2025 revenue of $433.8 million, missing consensus estimates by $5.8 million [1]. - The company experienced a net loss of $87.7 million, a substantial increase from a net loss of $12.98 million in the same period the previous year [1]. - Full-year 2025 expected revenue has been revised down to $17 million at the midpoint, with adjusted EPS projected at $0.50 [1]. Management Commentary - CEO Bruce Lowthers indicated that a last-minute client shutdown led to several million-dollar write-downs in Q3 [1]. - The company is facing challenges in a lower-tier market, particularly with high-risk Merchant Category Codes (MCC), which are difficult for banks to underwrite [1]. - Lowthers acknowledged ongoing difficulties with certain MCC codes and the company's efforts to navigate these challenges [1]. Stock Market Reaction - Following the announcement of the financial results, Paysafe's stock price fell by $2.80 per share, or 27.6%, closing at $7.36 per share on November 13, 2025 [1].

Core Viewpoint - A class action lawsuit has been filed against PomDoctor Ltd. for alleged securities fraud and unlawful business practices, with a significant drop in share price following a promotional scheme [1] Group 1: Class Action Lawsuit Details - The lawsuit is focused on whether PomDoctor and its officers engaged in securities fraud [1] - Investors have until April 6, 2026, to apply as Lead Plaintiff if they purchased PomDoctor securities during the Class Period [1] Group 2: Share Price Movement - PomDoctor's share price increased from $4.00 to an all-time high of $6.09 before crashing by approximately 91% to $0.50 on December 10, 2025 [1] - The price surge occurred without any fundamental news from the company, raising concerns about the legitimacy of the increase [1] Group 3: Allegations of Fraud - Investigations revealed that PomDoctor allegedly used social media for a "pump and dump" scheme, misleading investors through impersonation and baseless claims [1] - The promotional activities created a buying frenzy among retail investors, leading to significant financial losses [1]

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ramaco Resources, Inc. of Class Action Lawsuit and Upcoming Deadlines - METC [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ramaco Resources, Inc. ("Ramaco" or the "Company") (NASDAQ: METC). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4-POMLAW), toll-free, ...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in China Liberal Education Holdings Limited of Class Action Lawsuit and Upcoming Deadlines - CLEUF [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against China Liberal Education Holdings Limited ("CLEU" or the "Company") (OTCMKTS: CLEUF). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581 ...

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud and unlawful business practices, with a deadline for investors to join the lawsuit by April 6, 2026 [1]. Company Developments - On July 9, 2025, Ultragenyx and Mereo BioPharma Group announced progress in the Phase 3 Orbit study for UX143 (setrusumab) in patients with osteogenesis imperfecta, with a final analysis expected by the end of the year [1]. - Following this announcement, Ultragenyx's stock price dropped by $10.41, or 25.11%, closing at $31.04 on July 10, 2025 [1]. - On December 29, 2025, Ultragenyx reported that its Phase III Orbit and Cosmic Studies did not achieve statistical significance in their primary endpoints, leading to a further stock price decline of $14.47, or 42.32%, closing at $34.19 [1]. Legal Context - The class action lawsuit is focused on whether Ultragenyx and its executives engaged in fraudulent activities that misled investors [1]. - Pomerantz LLP, the law firm handling the case, has a history of successful litigation in securities fraud and corporate misconduct cases [1].